Skip to main content
. Author manuscript; available in PMC: 2013 Aug 19.
Published in final edited form as: Thorax. 2011 Aug 8;67(1):12–18. doi: 10.1136/thoraxjnl-2011-200393

Table 3.

VX-809 Pharmacokinetic parameters following once-daily dosing of VX-809 for 28 days

Day 1 Day 28 Day 28/day 1 AUC AR
Dose Parameter Cmax (µg/ml) tmax (h) AUC0–24 h (µg×h/ml) Cmax (µg/ml) tmax* (h) AUC0–24 h (µg×h/ml) CLss/F (l/h) Vz/F (litres) t1/2λz (h)
25 mg n 18 18 18 17 17 17 17 17 17 17
Mean 0.760 3.5* 7.20 1.10 4.0* 12.9 2.20 62.6 18.3 1.85
SD 0.280 1.5–9.0† 2.19 0.44 2.9–12.0† 4.9 0.80 99.0 20.5 0.70
50 mg n 18 18 18 17 17 17 17 17 17 17
Mean 1.85 3.1* 16.6 2.66 3.1* 28.8 2.31 54.6 17.3 1.67
SD 0.70 1.5–12.1† 6.3 1.01 0.8–9.0† 13.1 1.48 35.2 8.9 0.49
100 mg n 17 17 17 16 16 16 16 16 16 16
Mean 2.93 3.0* 29.0 4.62 3.1* 54.0 2.40 48.4 15.2 1.81
SD 0.92 1.6–6.2† 11.5 1.84 1.5–6.0† 31.5 1.30 25.4 7.2 0.60
200 mg n 19 19 19 18 18 18 18 18 18 18
Mean 6.41 4.0* 59.6 10.3 3.0* 118 2.09 46.0 15.6 2.01
SD 2.55 1.5–6.0† 26.3 4.5 1.5–6.1† 73 0.86 22.6 5.3 0.64
*

Median.

†

MineMax range.

AR, accumulation ratio; AUC0–24 h, area under the plasma concentration versus time curve from time 0 to 24 h; Cmax, maximum observed drug concentration; CLss/F, oral clearance at steady state; t1/2λz, apparent terminal half-life; tmax, time to reach Cmax after dosing; Vz/F, apparent volume of distribution.